SCHEMBL288790

SCHEMBL288790

FC(F)(F)[C]1CCCCC1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
TRIM24 O15164 1/20 0.32
TRIM33 Q9UPN9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7775536 1.00 ALDH1A1 (0.32) ALDH1A1TRIM24TRIM33
SCHEMBL1886237 0.96
SCHEMBL601895 0.89
SCHEMBL28087155 0.73
SCHEMBL3656726 0.73
SCHEMBL5281396 0.73
SCHEMBL8356448 0.73
SCHEMBL8507378 0.69
SCHEMBL1171187 0.69 NR1H2 (0.32)
SCHEMBL10465209 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 533 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024126648-A1 SULFOXIMINES AS INHIBITORS OF NaV1.8 Grünenthal GmbH (DE) 2024-06-20 WO claimed
EP-4385979-A1 MULTICYCLIC INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2024-06-19 EP claimed
EP-4385984-A1 PYRIDINE-N-OXIDES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2024-06-19 EP claimed
EP-4385980-A1 INDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2024-06-19 EP claimed
WO-2024092185-A1 ACYL SULFONAMIDE COMPOUNDS AS INHIBITORS OF POLYOMAVIRUS VIA NOVA THERAPEUTICS, INC. (US) 2024-05-02 WO claimed
US-20240002395-A1 COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN THE JOHNS HOPKINS UNIVERSITY 2024-01-04 US claimed
EP-4255893-A1 COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN The Johns Hopkins University (US) 2023-10-11 EP claimed
EP-4196480-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF Betta Pharmaceuticals Co., Ltd (CN) 2023-06-21 EP claimed
EP-4021441-A1 MEMBRANE-ACTIVE ANTI-BACTERIAL COMPOUNDS AND USES THEREOF Trustees of Dartmouth College (US) 2022-07-06 EP claimed
WO-2022119823-A1 COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN THE JOHNS HOPKINS UNIVERSITY (US) 2022-06-09 WO claimed
WO-2000018723-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed
CN-1193961-A Substituted benzylaminopiperidine compounds PFIZER (US) 1998-09-23 CN claimed
EP-0861235-A1 SUBSTITUTED BENZYLAMINOPIPERIDINE COMPOUNDS PFIZER INC. (US) 1998-09-02 EP claimed
WO-1997008144-A1 SUBSTITUTED BENZYLAMINOPIPERIDINE COMPOUNDS PFIZER PHARMACEUTICALS INC. (JP) 1997-03-06 WO claimed
US-4687507-A HERBICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-08-18 US claimed
US-4627873-A HERBICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-12-09 US claimed
EP-0030138-B1 HERBICIDAL SULFONAMIDES, AND COMPOSITIONS, PREPARATION AND USE THEREOF E.I. DU PONT DE NEMOURS AND COMPANY (US) 1984-06-13 EP claimed
EP-0007687-B1 SULFONAMIDES, PROCESSES FOR THEIR PREPARATION, COMPOSITIONS CONTAINING SAID SULFONAMIDES AND A METHOD FOR CONTROLLING THE GROWTH OF VEGETATION E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-03-30 EP claimed
EP-0030138-A1 Herbicidal sulfonamides, and compositions, preparation and use thereof E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-06-10 EP claimed
EP-0007687-A1 Sulfonamides, processes for their preparation, compositions containing said sulfonamides and a method for controlling the growth of vegetation E.I. DU PONT DE NEMOURS AND COMPANY (US) 1980-02-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002395-A1 COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN MRGPRX1, MRGPRX4, MRGPRX2 ALDH1A1 4126/4885TRIM24 1767/4885TRIM33 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.